It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
The latest research on chronic myeloid leukemia (CML) presented at the 2024 American Society of Hematology 2024 Annual Meeting and Exposition is reported by Dr Jorge Cortes from Georgia Cancer Center ...
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML). In a study involving patients with CML in high-income countries, approximately half the patients who ...
CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...
IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF). This is an ASCO Meeting Abstract from ...
Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results